Data on Sarepta Therapeutics’s experimental gene therapy for a rare type of muscular dystrophy showed that patients receiving a higher dose of the medicine saw greater benefits than those receiving a lower dose, delivering another early-stage win for the drug developer.
from The Boston Globe https://ift.tt/30l9CvZ
Bailey Lipschultz
Data on Sarepta Therapeutics’s experimental gene therapy for a rare type of muscular dystrophy showed that patients receiving a higher dose of the medicine saw greater benefits than those receiving a lower dose, delivering another early-stage win for the drug developer.
https://ift.tt/3dGjHHP June 09, 2020 at 01:45AM
ليست هناك تعليقات:
إرسال تعليق